CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push
Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.
Champions Oncology Q4 Earnings Call Highlights
Champions Oncology NASDAQ: CSBR reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or TOS, services business and efforts to bring radiopharmaceutical work in-house.
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
2 Microcaps With Gross Margin Catalysts
CSBR and CEPL have levers in place for Gross Margin improvement.
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation
Discover why Zacks rates Champions Oncology as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore CSBR's accelerating pharmacology services and expanding data initiatives amid execution risks and commercialization timing.
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
Champions Oncology (CSBR) Q4 2025 Earnings Call Transcript
Champions Oncology (NASDAQ:CSBR ) Q4 2025 Earnings Call July 23, 2025 4:30 PM ET Company Participants David Barry Miller - Chief Financial Officer Ronnie Morris - CEO & Director Conference Call Participants Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Operator Greetings. Welcome to the Champions Oncology Fourth Quarter Fiscal Year 2025 Earnings Call.
Champions Oncology: Biological IP Is The Real Asset - Not Preclinical Services
Champions Oncology is transitioning from a traditional CRO to also a high-margin data licensing platform, unlocking new revenue and margin potential. The market undervalues CSBR, not reflecting its evolving business model and scalable, defensible oncology data assets in its current valuation. CSBR's unique, clinically-annotated PDX dataset and early AI/data licensing deals offer significant future upside as the business scales.
Champions Oncology, Inc. (CSBR) Q3 2025 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2025 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Maj Soueidan - GeoInvesting George Marema - Pareto Ventures Operator Greetings. Welcome to the Champions Oncology Third Quarter Fiscal Year 2025 Earnings Call [Operator Instructions].
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy. The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities.
Champions Oncology: Right Point To Own In The Cycle Thanks To Operating Efficiencies
Champoins Oncology broke out of a multiyear downtrend following its Q2'25 earnings. Management has embarked on a one-way journey to reduce working capital and grow the business with zero incremental capital. This has succeeded and the business is now in a prime position to grow sales at 10% CAGR to CY'26 in my opinion.
